If necessary, use antiarrhythmic drugs to treat acute and chronic supraventricular tachycardia in infants
Supraventricular tachycardia (SVT) is the most common arrhythmia in infants. Older children and adults with SVT are commonly managed with catheter ablation of the SVT substrate; however, such treatment is the last resort in infants because the risks of the procedure outweigh its benefits and most SVTs in infants resolve spontaneously in the first year of life. SVT in infants is generally managed with electrical cardioversion, vagal manoeuvres and antiarrhythmic drugs (e.g. adenosine, esmolol and procainamide as acute therapy, and digoxin and class Ic, II or III antiarrhythmics, most commonly propranolol, as chronic therapy).
Compliance with ethical standards
Conflict of interest
The article was adapted from Pediatric Drugs 2017;19(6):539–51  by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.
The preparation of this review was not supported by any external funding.
- 1.American Heart Association. Tachycardia: fast heart rate. http://www.heart.org/HEARTORG/Conditions/Arrhythmia/AboutArrhythmia/Tachycardia-Fast-Heart-Rate_UCM_302018_Article.jsp#.WwNVj01lIRA. Accessed 21 May 2018.
- 5.Patti L, Gossman WG. Rhythm, tachycardia, supraventricular (SVT). Treasure Island: StatPearls Publishing. 2017. https://www.ncbi.nlm.nih.gov/books/NBK441972/. Accessed 17 May 2018.
- 11.Betapace/Betapace AF (sotalol hydrochloride) tablets: US prescribing information. Zug, Switzerland: Covis Pharma: 2016.Google Scholar